Adults 19 to 80, any sex, with Lung Neoplasm or Thoracic Surgery, Video-Assisted. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Accuracy of Lung Nodule LocalizationPrimary· From the time of completing final CT scan, assessed up to 2 days.
Localization accuracy was defined by the localizer deviation between the hookwire and the center of the target nodule. (The deviation was measured using CAD software after downloading the CT images from the Picture Archiving and Communication Systems.)
Group
Value
95% CI
CT-guided Localization
9.6
± 5.8
Template-guided Localization
8.7
± 6.9
Procedural Duration of the Nodule LocalizationSecondary· From the time of completing final CT scan, assessed up to 1 hour.
Procedural duration was derived from CT scan parameters, which was calculated as the time length between the initial and final scan.
Group
Value
95% CI
CT-guided Localization
9.5
± 3.6
Template-guided Localization
7.4
± 3.2
Radiation DoseSecondary· From the time of completing final CT scan, assessed up to 1 hour.
Radiation dosage was read on the monitor screen of CT scanner and converted to effective dosage.
Group
Value
95% CI
CT-guided Localization
313
± 84
Template-guided Localization
229
± 65
Complication RateSecondary· From the time of completing final CT scan, assessed up to 2 days.
Pnuemothorax related to lung nodule localization
Group
Value
95% CI
CT-guided Localization
17
Template-guided Localization
10
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event were assessed immediately after lung nodule localization through CT scanning, assessed up to 2 days..
Reporting threshold: 1%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The trial is to evaluate the efficacy and safety of three-dimensional printed navigational template in the clinical application of small peripheral lung nodule localization.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06780098 — Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell
· Phase 2
· recruiting
NCT06638398 — Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules
· NA
· active not recruiting
NCT06158971 — Feasibility Study of the Microwave Ablation System for Lung Tissue Ablation
· NA
· recruiting
NCT06254196 — Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates
· NA
· recruiting
NCT06419114 — Exploration of Optical Coherence Tomography-Guided Transbronchial Biopsy in Peripheral Pulmonary Lesions
· recruiting
Other Chang Chen trials
Trials by the same sponsor.
NCT07351565 — Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Canc
· Phase 1
· not yet recruiting
NCT07243964 — Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation
· recruiting
NCT05542992 — Deep Learning Model for Pure Solid Nodules Classification
· unknown
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chang Chen
Last refreshed: 19 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02952261.